{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:27:52Z","timestamp":1782167272885,"version":"3.54.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Follicular lymphoma (FL) is an indolent B-cell neoplasm of germinal center origin. Standard treatment regimens consist of anti-CD20 therapy with or without chemotherapy. While high response rates to initial therapy are common, patients ultimately relapse or have progressive disease. Clinical risk factors such as the Follicular Lymphoma International Prognostic Index (FLIPI) have been identified, but there is a need for prognostic and predictive biomarkers. We studied markers of lymphoma cells and tumor microenvironment by immunohistochemistry in tissue samples from patients enrolled in 1 of 4 phase 2 trials of anti\u2013CD20-based biological therapy for previously untreated grades 1 to 2 or 3A FL. Results were correlated with progression-free survival (PFS) and PFS status at 24 months. The 4 trials included 238 patients (51.1% male, median age: 55\u2009y) with stage III, IV, or bulky stage II disease. By FLIPI, 24.6% had low-risk, 56.8% had intermediate-risk, and 18.6% had high-risk disease. The outcome differed significantly for patients treated with lenalidomide and rituximab (CALGB 50803) compared with the other 3 trials (median: PFS not reached vs. 3.0\u2009y, hazard ratio=3.47, 95% confidence interval: 2.11-5.72); therefore, data were stratified by clinical trial (CALGB 50803 vs. all others) and adjusted for FLIPI risk group. Among 154 patients with available tissue, interfollicular BCL6 positivity, interfollicular CD10 positivity, and elevated Ki67 proliferation index \u226530% within neoplastic follicles were each associated with inferior PFS and a high risk of the early event by PFS status at 24 months. We identify promising biomarkers for FL risk stratification that warrant further validation in phase 3 trials.<\/jats:p>","DOI":"10.1097\/pas.0000000000001609","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T02:04:01Z","timestamp":1604282641000},"page":"384-393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti\u2013CD20-based Biological Therapy"],"prefix":"10.1097","volume":"45","author":[{"given":"Aliyah R.","family":"Sohani","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Giri","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandelyn","family":"Pitcher","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"Alliance Statistics and Data Center, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Said","sequence":"additional","affiliation":[{"name":"UCLA Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Celgene, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara A.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Medstar Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11864-018-0550-0","article-title":"Follicular lymphoma: past, present, and future","volume":"19","author":"Becnel","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdp460","article-title":"Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study","volume":"21","author":"Sweetenham","year":"2010","journal-title":"Ann Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00000478-200006000-00010","article-title":"CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas","volume":"24","author":"Dogan","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1309\/TNKL7GDC66R9WPV5","article-title":"Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma","volume":"121","author":"Bilalovic","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1309\/B6MK-J7NF-A6JP-X56K","article-title":"Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas","volume":"115","author":"Eshoa","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1080\/10428190701665954","article-title":"Biologic predictors in follicular lymphoma: importance of markers of immune response","volume":"48","author":"Kelley","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","article-title":"Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study","volume":"118","author":"Laurent","year":"2011","journal-title":"Blood"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann Oncol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.15768","article-title":"Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)","volume":"185","author":"Rosenbaum","year":"2019","journal-title":"Br J Haematol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/hupa.2002.127438","article-title":"Application of tissue microarray technology to the study of non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma","volume":"33","author":"Hedvat","year":"2002","journal-title":"Hum Pathol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.18632\/oncotarget.2605","article-title":"Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2","volume":"5","author":"McCarthy","year":"2014","journal-title":"Oncotarget"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bjc.2015.291","article-title":"Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma","volume":"113","author":"Nelson","year":"2015","journal-title":"Br J Cancer"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1309\/AJCPTMA1F6LWYTQV","article-title":"Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas","volume":"140","author":"Samols","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08420.x","article-title":"The role of BCL6 in lymphomas and routes to therapy","volume":"152","author":"Wagner","year":"2011","journal-title":"Br J Haematol"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"2040620718820510","DOI":"10.1177\/2040620718820510","article-title":"Novel treatment approaches and future perspectives in follicular lymphoma","volume":"10","author":"Sutamtewagul","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:04:50Z","timestamp":1749420290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001609","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}